| Authors: |
Armstrong AW; Department of Dermatology, University of California Los Angeles, Los Angeles, California., Gooderham MJ; SKiN Centre for Dermatology, Peterborough, Ontario, Canada; Department of Medicine, Queen's University, Kingston, Ontario, Canada; Probity Medical Research, Waterloo, Ontario, Canada., Eyerich K; Department of Dermatology, University of Freiburg, Freiburg, Germany., Reich K; Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, Hamburg, Germany., Blauvelt A; Blauvelt Consulting, LLC, Annapolis, Maryland., Hong HC; Probity Medical Research, Waterloo, Ontario, Canada; Department of Dermatology and Skin Science, University of British Columbia, Vancouver, British Columbia, Canada., Edwards RA; Health Services Consulting Corporation, Boxborough, Massachusetts., Bonfanti G; Engineering Ingegneria Informatica, Milan, Italy., Clibborn C; Pfizer Ltd., Tadworth, Surrey, United Kingdom., Biswas P; Clinical Research, Pfizer Inc., New York, New York., Chan G; Inflammation & Immunology, Pfizer Inc., Groton, Connecticut., Feeney C; Pfizer Ltd., Tadworth, Surrey, United Kingdom., Güler E; Inflammation & Immunology, Pfizer Inc., Istanbul, Turkey. Electronic address: erman.guler@pfizer.com. |